We are live on ! Find out more
ACRS icon

Aclaris Therapeutics
ACRS

136 hedge funds and large institutions have $409M invested in Aclaris Therapeutics in 2026 Q1 according to their latest regulatory filings, with 33 funds opening new positions, 41 increasing their positions, 40 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

126% more call options, than puts

Call options by funds: $2.57M | Put options by funds: $1.14M

106% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 16

62% more capital invested

Capital invested by funds: $252M → $409M (+$157M)

13.27% more ownership

Funds ownership: 77.29% → 90.56% (+13%)

11% more funds holding

Funds holding: 122 → 136 (+14)

3% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 40

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
136
Holders Change
+14
Holders Change %
+11.48%
% of All Funds
1.67%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
33
Increased
41
Reduced
40
Closed
16
Calls
$2.57M
Puts
$1.14M
Net Calls
+$1.43M
Net Calls Change
-$2.06M

Top Buyers

1
DTC
Deep Track Capital
Connecticut
+$31.5M
2
RCM
RA Capital Management
Massachusetts
+$23M
3
FLSM
Frazier Life Sciences Management
California
+$16.6M
4
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$11.3M
5
KCM
Kalehua Capital Management
Texas
+$6.18M

Top Sellers

1
VC
Vivo Capital
California
-$7.5M
2
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$4.03M
3
Morgan Stanley
Morgan Stanley
New York
-$2.26M
4
Renaissance Technologies
Renaissance Technologies
New York
-$2.1M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$1.97M
Name Holding Trade Value Shares
Change 		Change in
Stake
SAM
126
Smartleaf Asset Management
Massachusetts
$1.31K – – –
Nisa Investment Advisors
127
Nisa Investment Advisors
Missouri
$1.19K – – –
CFM
128
Cornerstone Financial Management
Massachusetts
$1.01K – – –
TC
129
Truvestments Capital
Florida
$563 – – –
SS
130
SBI Securities
Japan
$251 -$40 -12 -15%
AF
131
Allworth Financial
California
$184 +$165 +49 New
RFP
132
Root Financial Partners
California
$101 +$91 +27 New
RIL
133
Rothschild Investment LLC
Illinois
$34 +$3 +1 +13%
EP
134
Essential Partners
California
$19 – – –
MCM
135
MAI Capital Management
Ohio
$4 +$3 +1 New
Ameriprise
136
Ameriprise
Minnesota
– -$958K -318,426 Closed
Two Sigma Advisers
137
Two Sigma Advisers
New York
– -$769K -255,400 Closed
SFCM
138
Seven Fleet Capital Management
California
– -$323K -107,419 Closed
Point72 Asset Management
139
Point72 Asset Management
Connecticut
– -$262K -87,175 Closed
Man Group
140
Man Group
United Kingdom
– -$128K -42,435 Closed
VFA
141
Valeo Financial Advisors
Indiana
– -$82.9K -27,540 Closed
Jane Street
142
Jane Street
New York
– -$91.8K -27,216 Closed
AC
143
AXQ Capital
New Jersey
– -$72.8K -24,186 Closed
PAP
144
Persistent Asset Partners
Hong Kong
– -$67K -22,259 Closed
Mariner
145
Mariner
Kansas
– -$50.2K -16,670 Closed
Group One Trading
146
Group One Trading
Illinois
– -$42K -12,433 Closed
RS
147
R Squared
Hong Kong
– -$37.3K -12,408 Closed
AB
148
Amalgamated Bank
New York
– -$9K -2,883 Closed
Royal Bank of Canada
149
Royal Bank of Canada
Ontario, Canada
– -$8.54K -2,530 -97%
Osaic Holdings
150
Osaic Holdings
Arizona
– -$2.2K -730 Closed
3 4 5
6
7

ACRS Hedge Fund Activity: Q1 2026 in Review

136 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Aclaris Therapeutics (ACRS) for Q1 2026, worth a combined $409M — up 62% from $252M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new ACRS positions and 16 closed out — a net gain of 17 holders — while 41 added to existing stakes and 40 trimmed.

The largest buyer was Deep Track Capital, opening a new position worth an estimated $31.5M. The largest seller was Vivo Capital, cutting an estimated $7.5M.

  • 136 institutional investors held Aclaris Therapeutics (ACRS) as of Q1 2026, up from 122 in Q4 2025.
  • Funds reported $409M of Aclaris Therapeutics stock for Q1 2026, up 62% quarter-over-quarter.
  • 33 funds opened new Aclaris Therapeutics positions in Q1 2026 and 16 closed out, a net change of +17 holders.
  • The largest Aclaris Therapeutics buyer in Q1 2026 was Deep Track Capital, an estimated $31.5M added.
  • The largest Aclaris Therapeutics seller in Q1 2026 was Vivo Capital, an estimated $7.5M sold.

Based on aggregated 13F filings for Q1 2026.